P. Mclaughlin et al., RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM, Journal of clinical oncology, 16(8), 1998, pp. 2825-2833
Purpose: The CD20 antigen is expressed on more than 90% of B-cell lymp
homas. it is appealing for targeted therapy, because it does not shed
or modulate. A chimeric monoclonal antibody more effectively mediates
host effector functions and is itself less immunogenic than are murine
antibodies. Patients and Methods: This was a multiinstitutional trial
of the chimeric anti-CD20 antibody, IDEC-C2B8. Patients with relapsed
low grade or follicular lymphoma received on outpatient treatment cou
rse of IDEC-C2B8 375 mg/m(2) intravenously weekly for four doses. Resu
lts: From 31 centers, 166 patients were entered. Of this intent-to-tre
at group, 48% responded. With a median follow-up duration of 11.8 mont
hs, the projected median time ta progression for responders is 13.0 mo
nths. Serum antibody levels were sustained longer after the fourth inf
usion than after the first, and were higher in responders and in patie
nts with lower tumor burden. The majority of adverse events occurred d
uring the first infusion and were grade 1 or 2; fever and chills were
the most common events. Only 12% of patients had grade 3 and 3% grade
4 toxicities. A human antichimeric antibody was detected in only one p
atient. Conclusion: The response rate of 48% with IDEC-C2B8 is compara
ble to results with single-agent cytotoxic chemotherapy. Toxicity was
mild. Attention needs to be paid to the rate of antibody infusion, wit
h titration according to toxicity. Further investigation of this agent
is warranted, including its use in conjunction with standard chemothe
rapy. J Clin Oncol 16:2825-2833. (C) 1998 by American Society of Clini
cal Oncology.